Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
Medrxiv : the Preprint Server for Health Sciences
|
March 22, 2023
Integrating 4 Measures to Evaluate Physical Function in Patients with Cancer (In4M): Protocol for a prospective study
Gita Thanarajasingam, Paul G Kluetz, Vishal Bhatnagar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery
Michael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
The Lancet. Oncology
|
July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
Jaleh Fallah, Lijun Zhang, Anup Amatya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2020
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
Jennifer J Gao, Christy L Osgood, Yutao Gong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 13, 2021
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
Denise Casey, Suzanne Demko, Arup Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
Melanie Royce, Mirat Shah, Lijun Zhang, et al.
Eclinicalmedicine
|
October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable
Christina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
The Lancet. Oncology
|
April 17, 2025
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop
Madeline Pe, Caroline Voltz-Girolt, Jill Bell, et al.
JAMA
|
May 17, 2022
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines
Samantha Cruz Rivera, Olalekan Lee Aiyegbusi, Jonathan Ives, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting
Jennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
Medrxiv : the Preprint Server for Health Sciences
|
March 22, 2023
Integrating 4 Measures to Evaluate Physical Function in Patients with Cancer (In4M): Protocol for a prospective study
Gita Thanarajasingam, Paul G Kluetz, Vishal Bhatnagar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery
Michael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
The Lancet. Oncology
|
July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
Jaleh Fallah, Lijun Zhang, Anup Amatya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2020
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
Jennifer J Gao, Christy L Osgood, Yutao Gong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 13, 2021
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
Denise Casey, Suzanne Demko, Arup Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
Melanie Royce, Mirat Shah, Lijun Zhang, et al.
Eclinicalmedicine
|
October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable
Christina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
The Lancet. Oncology
|
April 17, 2025
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop
Madeline Pe, Caroline Voltz-Girolt, Jill Bell, et al.
JAMA
|
May 17, 2022
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines
Samantha Cruz Rivera, Olalekan Lee Aiyegbusi, Jonathan Ives, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting
Jennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.
Page
of 8